PR
Prime Medicine, Inc.
PRME · NASDAQ
$3.12 +0.00% (+$0.00)
1M -7.96%
Market Cap $567.1M
P/E Ratio -
Div. Yield -
ROE 188.27%
Piotroski F-Score Weak
2/9Valuation
0 /100
Expensive P/B 14.25x
P/S 139.24x
EV/EBITDA N/A
Growth
0 /100
Declining Book val. growth 27.43%
Rev. growth N/A
FCF growth N/A
Profitability
0 /100
Weak Net margin 4,613.11%
Op. margin 4,824.94%
FCF margin 3,850.92%
Quality
0 /100
Poor ROE 188.27%
ROA 75.45%
Asset turnover 0.02x
Debt
33 /100
High Current ratio 3.05x
Debt/Equity 2.83x
Net debt/EBITDA N/A
Stability
22 /100
Unstable EPS volatility 40.70%
Profitable years 0
Beta 2.35x
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na PRME
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Allan Reine
Employees
146
Headquarters
Cambridge
Nadcházející události
06 LIS
Earnings
Upcoming earnings report